# US 2020/0268649 A1 · Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0268649 A1
- Document ID: US20200268649A1
- Status: Published application
- Kind: A1
- Application number: 16/826,485
- Filed: 2020-03-23
- Published: 2020-08-27
- Earliest claimed: 2010-04-03
- Inventors: Praful Doshi
- Web page: https://patentgrep.com/patent/US20200268649A1

## CPC

- A61K 9/0051: {Ocular inserts or implants}
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61L 31/10: Macromolecular materials
- A61L 31/145: {Hydrogels or hydrocolloids}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- B33Y 80/00: Products made by additive manufacturing
- C08F 2/20: with the aid of macromolecular dispersing agents
- C08F 2/48: by ultraviolet or visible light
- C08F 220/28: containing no aromatic rings in the alcohol moiety
- C08L 33/08: Homopolymers or copolymers of acrylic acid esters
- C08L 33/10: Homopolymers or copolymers of methacrylic acid esters
- G02B 1/043: {Contact lenses}
- A61L 12/00: Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L 12/084: {in a gaseous state}
- A61L 12/143: {Quaternary ammonium compounds}
- A61L 2300/00: Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L 2300/436: of receptors
- A61L 2420/08: Coatings comprising two or more layers
- C08F 220/282: {and containing two or more oxygen atoms}
- C08L 33/066: {containing -OH groups}
- C08L 39/06: Homopolymers or copolymers of N-vinyl-pyrrolidones
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- B33Y: ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- C08F: MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- G02B: OPTICAL ELEMENTS, SYSTEMS OR APPARATUS

## Abstract

The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures that alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating. A second aspect of the present invention is a method of making a medical device that incorporates a drug in at least one coating. A third aspect of the present invention is a method of using a medical device of the present invention to treat, prevent from having, prevent from developing, control, reduce the severity, or reduce the progression of a disease, disorder or condition of a subject.

## Claims

### Claim 1

A method of making a medical device contact lens for delivery of drug to the eye of a subject in need of treatment, prevention, reduction of severity, or reduction of progression of myopia, or a combination thereof, comprising:
1) providing a contact lens comprising a first surface and a second surface; and
2) depositing at least one coating on at least one of said first surface, said second surface, or a combination thereof;
i. wherein said depositing comprises at least in part additive digital three dimensional printing;
ii. further wherein said at least one coating comprises at least one three dimensional structure, said at least one three dimensional structure comprising:
i) at least one drug reservoir layer,
wherein said at least one drug reservoir layer comprises at least one drug to treat, prevent, reduce the severity of, reduce the progression of myopia, or a combination thereof; and
ii) at least one barrier layer;
wherein said at least one barrier layer can modulate the release of said at least one drug from said medical device.

### Claim 2 (depends on 1)

The method of making a medical device contact lens of claim 1,
wherein said medical device is stored in a packaging solution.

### Claim 3 (depends on 2)

The method of making a medical device contact lens of claim 2,
wherein said packaging solution comprises at least one comfort enhancing agent.

### Claim 4 (depends on 2)

The method of making a medical device contact lens of claim 2,
wherein said packaging solution comprises one or more drugs.

### Claim 5 (depends on 4)

The method of making a medical device contact lens of claim 4,
wherein said one or more drugs comprises an anti-muscarinic agent, a muscarinic antagonist, a muscarinic receptor antagonist, a dopamine agonist, or a combination thereof.

### Claim 6 (depends on 4)

The method of making a medical device contact lens of claim 4,
wherein said one or more drugs comprises atropine, atropine sulphate monohydrate, pirenzepine, racanisodamine, cyclopentolate, homatropine, scopolamine, telenzepine, nuvenzepine, rispenzepine, apomorphine, bromocriptine, quinpirole, levodopa, or a combination thereof.

### Claim 7 (depends on 1)

The method of making a medical device contact lens of claim 1,
wherein said at least one drug comprises an anti-muscarinic agent, a muscarinic antagonist, a muscarinic receptor antagonist, a dopamine agonist, or a combination thereof.

### Claim 8

The method of making a medical device contact lens 1,
wherein said at least one drug comprises atropine, atropine sulphate monohydrate, pirenzepine, racanisodamine, cyclopentolate, homatropine, scopolamine, telenzepine, nuvenzepine, rispenzepine, apomorphine, bromocriptine, quinpirole, levodopa, or a combination thereof.

### Claim 9 (depends on 1)

The medical device of claim 1,
wherein said contact lens comprises a soft contact lens, a hydrogel contact lens, a silicone hydrogel contact lens, a hard contact lens, a gas permeable contact lens, or a combination thereof.

### Claim 10 (depends on 1)

The medical device of claim 1,
wherein said contact lens comprises a pre-made contact lens or a pre-manufactured contact lens.

### Claim 11 (depends on 1)

The medical device of claim 1,
wherein said at least one coating is made in whole or in part by digital printing, 3D printing, digital 3D printing, or a combination thereof.

### Claim 12

A method of using a medical device contact lens for delivery of at least one drug to the eye of a subject in need of treatment, prevention, control, reduction of the severity, or reduction of progression of myopia, comprising:
a) providing a subject in need of treatment, prevention, control, or reduction of the severity of myopia;
b) operably engaging a medical device contact lens comprising one or more drugs with at least one eye of said subject;
wherein said medical device contact lens comprises:
a) a contact lens comprising a first surface and a second surface;
b) said contact lens further comprising at least one coating provided on at least a portion of said first surface, said second surface, or a combination thereof as opposed to within said contact lens, wherein said at least one coating comprises at least one drug;
1) said at least one coating comprising at least one three dimensional structure;
2) said at least one three dimensional structure comprising:
a. one or more drug reservoir layers; wherein said one or more drug reservoir layers comprise at least one drug; and
b. one or more barrier layers;
c) wherein said one or more barrier layers modulate the release of said one or more drugs from said contact lens;
d) wherein said one or more drug reservoir layers, said one or more barrier layers, or a combination thereof, are oriented vertically, horizontally, or a combination thereof, relative to each other;
further wherein said at least one drug can treat, prevent, control, reduce the severity, or reduce the progression of myopia in a subject in need thereof; and
further wherein said at least one drug is released from said contact lens in a pharmaceutically effective amount to treat, prevent, control, reduce the severity, or reduce the progression of myopia in a subject when said medical device is operably engaged with the eye of said subject.

### Claim 13 (depends on 12)

The method of using a medical device contact lens of claim 12,
wherein said medical device contact lens is stored in a packaging solution.

### Claim 14 (depends on 13)

The method of using a medical device contact lens of claim 13,
wherein said packaging solution comprises one or more comfort enhancing agents.

### Claim 15 (depends on 14)

The medical device of claim 14,
further wherein said one or more comfort enhancing agents is provided within said contact lens, on the surface of said contact lens, or a combination thereof.

### Claim 16 (depends on 13)

The method of using a medical device contact lens of claim 13,
wherein said packaging solution comprises one or more drugs.

### Claim 17 (depends on 16)

The method of using a medical device contact lens of claim 16,
wherein said one or more drugs comprise an anti-muscarinic agent, a muscarinic antagonist, a muscarinic receptor antagonist, a dopamine agonist, or a combination thereof.

### Claim 18 (depends on 16)

The method of using a medical device contact lens of claim 16,
wherein said one or more drugs comprise atropine, atropine sulphate monohydrate, pirenzepine, racanisodamine, cyclopentolate, homatropine, scopolamine, telenzepine, nuvenzepine, rispenzepine, apomorphine, bromocriptine, quinpirole, levodopa, or a combination thereof.

### Claim 19 (depends on 12)

The method of using a medical device contact lens of claim 12,
wherein said at least one drug comprise an anti-muscarinic agent, a muscarinic antagonist, a muscarinic receptor antagonist, a dopamine agonist, or a combination thereof.

### Claim 20 (depends on 12)

The method of using a medical device contact lens of claim 12,
wherein said at least one drug comprise atropine, atropine sulphate monohydrate, pirenzepine, racanisodamine, cyclopentolate, homatropine, scopolamine, telenzepine, nuvenzepine, rispenzepine, apomorphine, bromocriptine, quinpirole, levodopa, or a combination thereof.

### Claim 21 (depends on 12)

The method of using a medical device contact lens of claim 12,
wherein said medical device is provided as part of a system to treat, prevent, control, reduce the severity, or reduce the progression of myopia in a subject.

### Claim 22 (depends on 21)

The method of using a medical device contact lens of claim 21,
wherein said system comprises at least one packaging, at least one set of instructions, at least one solution, or a combination thereof.

### Claim 23 (depends on 12)

The method of using a medical device contact lens of claim 12,
wherein said contact lens comprises a multi-focal contact lens, a bifocal contact lens, orthokeratology contact lens, corrective contact lens, non-corrective contact lens, or a combination thereof.
